Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Public ClinicalTrials.gov record NCT03238911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside/Ferric Derisomaltose and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (Phosphare-IDA-04)
Study identification
- NCT ID
- NCT03238911
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pharmacosmos A/S
- Industry
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Interventions
- Iron isomaltoside/ferric derisomaltose Drug
- Ferric carboxymaltose Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 23, 2017
- Primary completion
- Jun 18, 2018
- Completion
- Jun 18, 2018
- Last update posted
- Feb 24, 2020
2017 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pharmacosmos Investigational Site | Los Angeles | California | 90036 | — |
| Pharmacosmos Investigational Site | Sacramento | California | 95831 | — |
| Pharmacosmos Investigational Site | Santa Ana | California | 92704 | — |
| Pharmacosmos Investigational Site | Clearwater | Florida | 33759 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33125 | — |
| Pharmacosmos Investigational Site 1 | Miami | Florida | 33126 | — |
| Pharmacosmos Investigational Site 2 | Miami | Florida | 33126 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33143 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33144 | — |
| Pharmacosmos Investigational Site | Indianapolis | Indiana | 46202 | — |
| Pharmacosmos Investigational Site | Wichita | Kansas | 67206 | — |
| Pharmacosmos Investigational Site | Metairie | Louisiana | 70001 | — |
| Pharmacosmos Investigational Site | Lancaster | Pennsylvania | 17605 | — |
| Pharmacosmos Investigational Site | Houston | Texas | 77024 | — |
| Pharmacosmos Investigational Site | Orem | Utah | 84058 | — |
| Pharmacosmos Investigational Site | Leesburg | Virginia | 20176 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03238911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03238911 live on ClinicalTrials.gov.